December 2023 in “Natural product research” Lignans from Urtica triangularis may help treat benign prostatic hyperplasia (BPH).
January 2023 in “Journal for ReAttach Therapy and Developmental Diversities” Carthamus oxyacantha may help treat BPH by inhibiting 5α-reductase.
Men with depression and marijuana usage are more likely to be treated for lower urinary tract symptoms/benign prostatic hyperplasia.
December 2021 in “Innovation in aging” Frailer men have a higher risk of worsening prostate problems and serious health events needing hospital care.
April 2020 in “The Journal of Urology” Big chain pharmacies in Pennsylvania charge significantly more for generic BPH medications than independent pharmacies, but independent pharmacies have more regional price variation.
April 2018 in “The Journal of Urology” Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
December 2016 in “The Journal of urology/The journal of urology” Castration significantly reduces prostate size and BPH symptoms.
September 2014 in “PubMed Central” BPH treatments can cause sexual side effects affecting quality of life.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
March 2014 in “The Journal of Urology” Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.
December 2013 in “Urology reports (St - Petersburg)” Sonirid Duo effectively treats benign prostatic hyperplasia.
Early balding may be a sign of future prostate problems.
Tamsulosin and finasteride together effectively slow down and prevent BPH progression.
September 2010 in “Zhonghua miniao waike zazhi” Tamsulosin hydrochloride is safe and effective for long-term treatment of urinary symptoms in BPH patients.
September 2010 in “European Urology Supplements” Statins do not impact BPH and LUTS progression when combined with finasteride.
June 2010 in “Urology times” Finasteride causes fewer sexual side effects than dutasteride in men with BPH.
March 2010 in “The Journal of Urology” Methylation of the 5-AR2 gene may cause resistance to Finasteride in BPH patients.
March 2009 in “The Journal of Urology” Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.
January 2009 in “Journal of Jilin Medical College” SDG helps reduce BPH effects in rats.
March 2008 in “European Urology Supplements” Finasteride and dutasteride can affect sexual function in BPH patients.
January 2008 in “Journal of Beijing Normal University” Terazosin hydrochloride helps with BPH and blood pressure, but not more than the control.
April 2006 in “The Journal of Urology” Genetic variations may affect how well finasteride works for BPH patients.
April 2004 in “Journal watch” Finasteride effectively reduces the need for surgery and urinary issues in men with BPH over the long term.
January 2004 in “Anticancer Research” Long-term antiandrogen use may increase aggressive prostate cancer risk.
January 2004 in “Zhongguo yiyuan yongyao pingjia yu fenxi” Using tamsulosin with finasteride is the most effective and reduces surgery risk for BPH.
February 2003 in “European Urology Supplements” Baseline PSA levels affect general health and sexual satisfaction in men with BPH treated with finasteride or placebo.
May 2017 in “Psychiatric news” BPH medications may increase the risk of self-harm and depression, especially in the first 18 months.
November 2022 in “Journal of the Endocrine Society” Correcting vitamin D and progesterone deficiencies can significantly improve hair loss, acne, and BPH symptoms.
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
January 2018 in “International Journal of Medical Research and Health Sciences” Finasteride reduces blood loss and the need for blood transfusions during and after TURP surgery.